SynthesisMedicine2018
The prognostic value of microRNA-183 in human cancers: A meta-analysis.
Synthesis in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Prognostic Value of MicroRNA-15a in Human Cancers: A Meta-Analysis and Bioinformatics.BioMed research international · 2019Pooled it
- eIF2Bδ blocks the integrated stress response and maintains eIF2B activity and cancer metastasis by overexpression in breast cancer stem cells.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- MicroRNA-183 cluster: a promising biomarker and therapeutic target in gastrointestinal malignancies.American journal of cancer research · 2023Review
- Expression of miR-127, miR-154, and miR-183 in Medullary Thyroid Carcinoma Tumors.Iranian journal of public health · 2021Article
- NGF/TRKA Decrease miR-145-5p Levels in Epithelial Ovarian Cancer Cells.International journal of molecular sciences · 2020Article
- Circulating RNAs as Potential Biomarkers in Amyotrophic Lateral Sclerosis.International journal of molecular sciences · 2020Review
- Review
- Review
- MicroRNAs in Alzheimer's Disease: Diagnostic Markers or Therapeutic Agents?Frontiers in pharmacology · 2019Review
- Upregulation of miR-183-5p predicts worse survival in patients with renal cell cancer after surgery.Cancer biomarkers : section A of Disease markers · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeveral studies have been conducted to explore the prognostic value of miR-183 in different types of cancer; however, their results were controversial. Therefore, the present meta-analysis was conducted to comprehensively evaluate the prognostic value of miR-183 expression level in cancer.
methodsA comprehensive literature search was carried out by searching PubMed and EMBASE database between January 1966 and April 2017. Fixed effect and random effect models were used to evaluate the pooled hazard risk (HR) and the relevant 95% confidence intervals (CIs). Subgroup analyses and sensitivity analysis were also carried out.
resultsA total of 12 studies published between 2011 and 2017 were included in the present meta-analysis. The meta-analysis result indicated that there was a significant association between miR-183 expression level and overall survival (HR = 2.642; 95%CI: 2.152-3.245), and there was a significant association between miR-183 expression level and tumor progression (HR = 2.403; 95%CI: 1.267-4.559). In subgroup analysis, we found that high expression level was significantly associated with poor prognosis in most cancers (HR = 2.824, 95%CI: 2.092-3.813); however, low miR-183 level was significantly associated with poor prognosis in melanoma and pancreatic ductal adenocarcinoma (HR = 2.322, 95%CI: 1.337-4.031).
conclusionsThe results of our meta-analysis indicated that the highly expressed miR-183 might predict poor survival of patients with most cancer types, whereas the downregulated miR-183 level might be associated with poor prognosis in patients with melanoma and pancreatic ductal adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.